Evolutionary intelligence for autoimmune disease
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology. Viruses, ticks, and worms have experimented over millions of years to create proteins that control the human immune system. We use AI to identify these proteins and engineer them into next-generation autoimmune therapies.
Our team is three PhD scientists from UCSF, UCSD, and UC Berkeley who have worked together for 3+ years in biotech. We have deep expertise in parasite biology, computational biology, and software for AI-based protein structure prediction
Total raised
$500K
Last stage
Seed
Investors
Dennis Sun
PhD in evolutionary and developmental biology from UC Berkeley, AB from Harvard. Previously Chief of Staff at a $500M biotech startup. Expert in evolutionary and computational biology.
Adair Borges
PhD from UCSF, Miller Fellow at UC Berkeley. 15+ years of host-parasite interaction research. 50+ publications including in Cell and Science, co-inventor on an anti-CRISPR patent.
LinkedInEmily Weiss
I'm a molecular and computational biologist working to revolutionize drug discovery for autoimmune disease. At Ditto, I lead the platform for engineering parasite-derived therapeutics. I hold a PhD in microbiology, genomics, and plant genetics, with a focus on sequencing, high-throughput screening, and computational pipeline development. Published in Nature Microbiology and eLife. Previously at Illumina, DuPont, and an early-stage biotech venture team.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.